OTCMKTS:IPHYF Innate Pharma (IPHYF) Stock Price, News & Analysis $1.65 0.00 (0.00%) As of 09/16/2026 Add Compare Share Share Stock Analysis Stock AnalysisChartFinancialsNews and TrendsSEC FilingsShort Interest About Innate Pharma Stock (OTCMKTS:IPHYF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Innate Pharma alerts:Sign Up Key Stats Today's Range$1.65▼$1.6550-Day Range$1.65▼$1.6552-Week Range$1.37▼$2.25VolumeN/AAverage VolumeN/AMarket Capitalization$138.32 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Innate Pharma S.A. is a France-based biotechnology company focused on developing immunotherapies for cancer. The company’s research is centered on the innate immune system, including natural killer cells and other immune mechanisms that can recognize and attack tumor cells. Its activities include drug discovery, clinical development and collaborations with pharmaceutical companies. Innate Pharma’s pipeline has included antibody-based therapies designed to stimulate or direct immune responses against cancer. Its lead investigational programs have included lacutamab, an antibody being developed for certain T-cell lymphomas, and other oncology candidates targeting immune checkpoints and tumor-associated pathways. The company has also advanced programs through strategic partnerships, including collaborations with AstraZeneca involving monalizumab and other immuno-oncology assets. Founded in 1999 and headquartered in Marseille, France, Innate Pharma conducts research and development activities in Europe and works with international pharmaceutical partners to advance its therapies. The company’s leadership has included Chief Executive Officer Mondher Mahjoubi, who has guided its development as a clinical-stage immuno-oncology business. Innate Pharma’s shares trade in the United States under the symbol IPHYF.AI Generated. May Contain Errors. Read More Receive IPHYF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innate Pharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IPHYF Stock News HeadlinesSobi partnership with Innate Pharma takes effectSeptember 17 at 3:10 AM | marketscreener.comMInnate Pharma Secures Sobi Partnership Cash and Extends Runway as Key Oncology Trials AdvanceSeptember 17 at 1:51 AM | tipranks.comTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. dollar reset - and most Americans don't know it's happening. The last time America underwent a monetary shift like this, under Nixon in the 1970s, it minted an average of 1,300 new millionaires a day for over half a century. Stansberry has released a new documentary naming the assets he believes are positioned to surge as a result.September 17 at 1:00 AM | Porter & Company (Ad)Innate Pharma to deliver H1 2026 business update via investor webcastSeptember 10, 2026 | tipranks.comInnate Pharma (IPHYF) Projected to Announce Quarterly Earnings on ThursdaySeptember 10, 2026 | americanbankingnews.comInnate Pharma to Highlight Oncology Pipeline at H.C. Wainwright Investment ConferenceSeptember 2, 2026 | tipranks.comInnate Pharma to Spotlight Oncology Pipeline at H.C. Wainwright Investor ConferenceSeptember 2, 2026 | tipranks.comInnate Pharma Raises €30 Million in Private Share Placement to Fund Oncology PipelineAugust 19, 2026 | tipranks.comSee More Headlines IPHYF Stock Analysis - Frequently Asked Questions How have IPHYF shares performed this year? Innate Pharma's stock was trading at $2.1550 at the beginning of 2026. Since then, IPHYF stock has decreased by 23.4% and is now trading at $1.65. How do I buy shares of Innate Pharma? Shares of IPHYF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Today9/17/2026Next Earnings (Estimated)9/17/2026Fiscal Year End12/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:IPHYF Previous SymbolNASDAQ:IPHYF CIK1598599 Webwww.innate-pharma.com Phone(343) 030-3030Fax33-04-30-30-30-00Employees179Year Founded1999Profitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.27 Quick Ratio1.27 Sales & Book Value Annual Sales$10.19 million Price / Sales13.57 Cash FlowN/A Price / Cash FlowN/A Book Value($0.29) per share Price / Book-5.69Miscellaneous Outstanding Shares83,830,000Free Float57,097,000Market Cap$138.32 million OptionableNot Optionable Beta0.28 Social Links The 7 Hottest IPO Stories of 2026MarketBeat just released its list of the 7 hottest IPOs expected to hit Wall Street in 2026. See which companies are preparing to go public and why investors are watching closely.Get This Free Report This page (OTCMKTS:IPHYF) was last updated on 9/17/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innate Pharma SA Please log in to your account or sign up in order to add this asset to your watchlist. Share Innate Pharma With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IPHYF Stock Alerts